ENOXACIN SESQUIHYDRATE

US Previously Marketed

First approved in 1991

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C15H17FN4O3.3H2O
Molecular Weight	694.6836
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.O.CCN1C=C(C(O)=O)C(=O)C2=C1N=C(N3CCNCC3)C(F)=C2.CCN4C=C(C(O)=O)C(=O)C5=C4N=C(N6CCNCC6)C(F)=C5

InChI

InChIKey=DKNNITGJCMPHKE-UHFFFAOYSA-N

InChI=1S/2C15H17FN4O3.3H2O/c2*1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20;;;/h2*7-8,17H,2-6H2,1H3,(H,22,23);3*1H2

HIDE SMILES / InChI

Molecular Formula	C15H17FN4O3
Molecular Weight	320.3189
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6226242 | https://www.ncbi.nlm.nih.gov/pubmed/8429114 | https://www.ncbi.nlm.nih.gov/pubmed/8494374

Enoxacin is an oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract infections and gonorrhea. Enoxacin is bactericidal drugs, eradicating bacteria by interfering with DNA replication. Like other fluoroquinolones, enoxacin functions by inhibiting bacterial DNA gyrase and topoisomerase IV. The inhibition of these enzymes prevents bacterial DNA replication, transcription, repair and recombination. Enoxacin is active against many Gram-positive bacteria. After oral administration enoxacin is rapidly and well absorbed from the gastrointestinal tract. The antibiotic is widely distributed throughout the body and in the different biological tissues. Tissue concentrations often exceed serum concentrations. The binding of enoxacin to serum proteins is 35 to 40%. The serum elimination half-life, in subjects with normal renal function, is approximately 6 hours. Approximately 60% of an orally administered dose is excreted in the urine as unchanged drug within 24 hours. Enoxacin, like other fluoroquinolones, is known to trigger seizures or lower the seizure threshold. The compound should not be administered to patients with epilepsy or a personal history of previous convulsive attacks as may promote the onset of these disorders.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Topoisomerase IV 62 Target ID: CHEMBL2363077 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18813225	Inhibitor 8297
Bacterial DNA gyrase 66 Target ID: CHEMBL2311224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9341164	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. 3 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8429	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 1991
Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis, or Staphylococcus saprophyticus 3 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8429	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 1991
Complicated urinary tract infections 11 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8429	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 1991

C_max

Value	Dose	Analyte	Population
7.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.58 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.02 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.83 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
25.75 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
29.08 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.67 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.35 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Doses

Dose	Population	Adverse events
600 mg single, oral Highest studied dose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	unhealthy, 41.9 years n = 79 Health Status: unhealthy Condition: cystitis Age Group: 41.9 years Sex: M+F Population Size: 79 Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	unhealthy, 43.8 years n = 75 Health Status: unhealthy Condition: cystitis Age Group: 43.8 years Sex: M+F Population Size: 75 Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/
600 mg 3 times / day multiple, oral (max) Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult n = 20060 Health Status: unhealthy Condition: Gram-negative urinary tract pathogens Age Group: adult Sex: M+F Population Size: 20060 Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	Other AEs: Gastrointestinal disorders, Epidermal and dermal conditions... Other AEs: Gastrointestinal disorders (1.3%) Epidermal and dermal conditions (0.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/

AEs

AE	Significance	Dose	Population
Epidermal and dermal conditions	0.4%	600 mg 3 times / day multiple, oral (max) Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult n = 20060 Health Status: unhealthy Condition: Gram-negative urinary tract pathogens Age Group: adult Sex: M+F Population Size: 20060 Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/
Gastrointestinal disorders	1.3%	600 mg 3 times / day multiple, oral (max) Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult n = 20060 Health Status: unhealthy Condition: Gram-negative urinary tract pathogens Age Group: adult Sex: M+F Population Size: 20060 Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 P-gp 1461	MATE1 135 OATP1A2 62	CYP1A2 701 CYP2B1 26 CYP2B2 15 CYP2E1 128 CYP3A1 4 CYP3A2 6 CYP4A1 17 CYP1A1 108

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A1 218	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2B1 41	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2B2 16	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2E1 970	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP3A1 5	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP3A2 13	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP4A1 25	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15543082/	no
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/8347124/;https://pubmed.ncbi.nlm.nih.gov/10096258/	yes [Inhibition 250 uM]	yes (co-administration study) Comment: enoxacin caused a 6-fold decrease in caffeine clearance Sources: https://pubmed.ncbi.nlm.nih.gov/8347124/;https://pubmed.ncbi.nlm.nih.gov/10096258/
CYP1A2 1692	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
MATE1 135	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/19004926/	yes
OATP1A2 62	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565919/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:157175	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:157175
ChemicalBook	CB2403021	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2403021
MolPort	MolPort-003-666-456	https://www.molport.com/shop/molecule-link/MolPort-003-666-456
Selleck Chemicals	Enoxacin(Penetrex)	http://www.selleckchem.com/products/Enoxacin(Penetrex).html
ZINC	ZINC000019594549	http://zinc15.docking.org/substances/ZINC000019594549
eMolecules	538022	https://www.emolecules.com/cgi-bin/more?vid=538022

PubMed

Title	Date	PubMed
Assessment of temafloxacin neurotoxicity in rodents.	1991 Dec 30	1662895
Hippocampus and frontal cortex are the potential mediatory sites for convulsions induced by new quinolones and non-steroidal anti-inflammatory drugs.	1991 Jun	1651287
Enoxacin acute liver injury.	1992 May	1506651
Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.	2000 Oct	10991859
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.	2000 Oct	10991858
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.	2001	11735605
Comparison of side effects of levofloxacin versus other fluoroquinolones.	2001	11549784
History of quinolones and their side effects.	2001	11549783
Quinolones and false-positive urine screening for opiates by immunoassay technology.	2001 Dec 26	11754677
Effect of liposomes and niosomes on skin permeation of enoxacin.	2001 May 21	11337166
Synthesis and antibacterial activity of some novel N-substituted piperazinyl-quinolones.	2001 Nov-Dec	11822230
Is more than one quinolone needed in clinical practice?	2001 Sep	11573860
Biphenylacetic acid enhances the antagonistic action of fluoroquinolones on the GABA(A)-mediated responses of the isolated guinea-pig ileum.	2001 Sep	11529690
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].	2002 Jun	12199111
[Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent--in vitro and in vivo studies].	2002 Jun	12199110
Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials.	2002 May 23	12014972
Antituberculosis agents. III. In vitro evaluation of antimycobacterial activity and cytotoxicity of some N-piperazinyl quinolone derivatives.	2002 May-Jun	12197426
Laser flash photolysis study of photoionization in fluoroquinolones.	2002 Nov	12659527
[The history of the development and changes of quinolone antibacterial agents].	2003	15143768
Corneal and scleral permeability of quinolones--a pharmacokinetics study.	2003 Dec	14733712
Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system.	2003 Feb	12696183
Direct determination of four fluoroquinolones, enoxacin, norfloxacin, ofloxacin, and ciprofloxacin, in pharmaceuticals and blood serum by HPLC.	2003 Mar	12638045
[Analysis of the response factors of different quinolones detected by evaporative light-scattering detector].	2003 Sep	14730921
Synthesis and in vitro antibacterial evaluation of N-[5-(5-nitro-2-thienyl)-1,3,4-thiadiazole-2-yl] piperazinyl quinolones.	2003 Sep	14561484
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.	2004 Apr	15047530
Validation of HPLC method for determination of six fluoroquinolones: cinoxacin, ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin.	2004 Dec	15909943
[Simultaneous determination of quinolones in foods by LC/MS/MS].	2004 Oct	15678937
A novel approach to estimate in vitro antibacterial potency of Chinese medicine using a concentration-killing curve method.	2005	16173540
Determination of fluoroquinolones in edible animal tissue samples by high performance liquid chromatography after solid phase extraction.	2005 Apr	15881086
Evaluation of phototoxic and photoallergic potentials of 13 compounds by different in vitro and in vivo methods.	2005 Apr 4	15792876
Celecoxib does not induce convulsions nor does it affect GABAA receptor binding activity in the presence of new quinolones in mice.	2005 Jan 10	15659296
Structure-phototoxicity relationship in Balb/c mice treated with fluoroquinolone derivatives, followed by ultraviolet-A irradiation.	2005 Jul 4	15917145
Induced and photoinduced DNA damage by quinolones: ciprofloxacin, ofloxacin and nalidixic acid determined by comet assay.	2005 Jul-Aug	15691228
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Interaction study between enoxacin and fluvoxamine.	2005 Jun	15905806
Direct determination of five fluoroquinolones in chicken whole blood and in veterinary drugs by HPLC.	2005 Mar	15792246
Antibacterial studies, DNA oxidative cleavage, and crystal structures of Cu(II) and Co(II) complexes with two quinolone family members, ciprofloxacin and enoxacin.	2005 Mar	15708788
Fluoroquinolone-resistant Campylobacter isolates from conventional and antibiotic-free chicken products.	2005 May	15866763
Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.	2005 May	15848290
Separation and determination of seven fluoroquinolones by pressurized capillary electrochromatography.	2005 Nov	16318219
Mutagenesis induced by 12 quinolone antibacterial agents in Escherichia coli WP2uvrA/pKM101.	2006 Apr	16171969
Effects of Transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes.	2006 Jan	16393463

Patents

Sample Use Guides

In Vivo Use Guide

Enoxacin should be taken at least one hour before or at least two hours after a meal. For treatment uncomplicated urethral or cervical gonorrhea: 400 mg single dose. For treatment uncomplicated urinary tract infections 200 mg q12h for 7 days. For treatment complicated urinary tract infections: 400 mg q12h for 14 days. Dosage should be adjusted in patients with a creatinine clearance value of 30 mL/min/1.73 m 2 or less.

Route of Administration: Oral

In Vitro Use Guide

The in vitro antibacterial activity of AT-2266 (Enoxacin ) was tested by the determination of minimal bactericidal concentrations (MBCs) and the reduction of viable cells during exposure to the drug for 24 h. MIC90s of AT-2266 for P. aeruginosa resistant to gentamicin and Enterobacteriaceae resistant to nalidixic acid were 3.13 and 12.5 mkg/ml, respectively

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:34:42 GMT 2023` Edited by `admin` on `Fri Dec 15 15:34:42 GMT 2023`
Record UNII	I9CD31N8WB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ENOXACIN SESQUIHYDRATE

Common Name

English

ENOXACIN SESQUIHYDRATE [MI]

Common Name

English

1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 1-ETHYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)-, HYDRATE (2:3)

Common Name

English

ENOXACIN HYDRATE

Common Name

English

ENOXACIN HYDRATE [JAN]

Common Name

English

Enoxacin sesquihydrate [WHO-DD]

Common Name

English

Code System Code Type Description

PUBCHEM

24840537